FALSE PHARMACORESISTANCE - A TRUE PROBLEM.

Acta Clin Croat

1Department of Neurology, Dubrava University Hospital, Zagreb, Croatia; 
2Department of Psychiatry and Neurology, Faculty of Dental Medicine and Health, 
Josip Juraj Strossmayer University, Osijek, Croatia; 
3Department of Neurology, Zadar General Hospital, Zadar, Croatia.

Published: December 2021

Pharmacoresistant epilepsy poses a great burden to patients, their families, and the whole healthcare system, with numerous social, economic, physical, and psychical consequences. Hence, it is a diagnosis that has to be made only in cases of high certainty, after all potential causes of epilepsy have been evaluated. One of the important causes of pharmacoresistant epilepsy is false pharmacoresistance, an entity that implies a condition in which poor disease control is not a consequence of the biology of the disease itself, antiepileptic drug inefficacy, and/or patient specificity. It is a consequence of human error and strongly depends on the experience of the treating physician, as well as on the attitude of the patient. Despite its 'falseness', this entity is accompanied by real consequences for the patient and his family, and at the same time, it delays appropriate treatment of the actual disease from which the patient is suffering. In order to introduce appropriate treatment and avoid unnecessary and harmful diagnostic procedures, false pharmacoresistance is a condition that has to be ruled out in any patient with difficult-to-treat seizures.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9590236PMC
http://dx.doi.org/10.20471/acc.2021.60.s3.01DOI Listing

Publication Analysis

Top Keywords

false pharmacoresistance
12
pharmacoresistant epilepsy
8
appropriate treatment
8
patient
5
pharmacoresistance true
4
true problem
4
problem pharmacoresistant
4
epilepsy poses
4
poses great
4
great burden
4

Similar Publications

Objective: We aim to improve focal cortical dysplasia (FCD) detection by combining high-resolution, three-dimensional (3D) magnetic resonance fingerprinting (MRF) with voxel-based morphometric magnetic resonance imaging (MRI) analysis.

Methods: We included 37 patients with pharmacoresistant focal epilepsy and FCD (10 IIa, 15 IIb, 10 mild Malformation of Cortical Development [mMCD], and 2 mMCD with oligodendroglial hyperplasia and epilepsy [MOGHE]). Fifty-nine healthy controls (HCs) were also included.

View Article and Find Full Text PDF

FALSE PHARMACORESISTANCE - A TRUE PROBLEM.

Acta Clin Croat

December 2021

1Department of Neurology, Dubrava University Hospital, Zagreb, Croatia; 
2Department of Psychiatry and Neurology, Faculty of Dental Medicine and Health, 
Josip Juraj Strossmayer University, Osijek, Croatia; 
3Department of Neurology, Zadar General Hospital, Zadar, Croatia.

Pharmacoresistant epilepsy poses a great burden to patients, their families, and the whole healthcare system, with numerous social, economic, physical, and psychical consequences. Hence, it is a diagnosis that has to be made only in cases of high certainty, after all potential causes of epilepsy have been evaluated. One of the important causes of pharmacoresistant epilepsy is false pharmacoresistance, an entity that implies a condition in which poor disease control is not a consequence of the biology of the disease itself, antiepileptic drug inefficacy, and/or patient specificity.

View Article and Find Full Text PDF

We present an illustrative case to address anterior temporal lobe atrophy with poor delineation of the temporopolar gray-white matter interface based on T2-weighted and fluid-attenuated inversion recovery (FLAIR) images in patients with temporal lobe epilepsy associated with hippocampal sclerosis (TLE-HS). A 52-year-old woman with pharmacoresistant seizures since the age of six months underwent a previous MRI scan using a suboptimal protocol which was reported as unremarkable. MRI performed according to an epilepsy protocol showed classic signs of left HS and ipsilateral temporal polar atrophy with blurring of the gray-white matter boundary on FLAIR images.

View Article and Find Full Text PDF

Purpose: Focal cortical dysplasias (FCDs) represent one of the most frequent causes of pharmaco-resistant focal epilepsies. Despite improved clinical imaging methods over the past years, FCD detection remains challenging, as FCDs vary in location, size, and shape and commonly blend into surrounding tissues without clear definable boundaries. We developed a novel convolutional neural network for FCD detection and segmentation and validated it prospectively on daily-routine MRIs.

View Article and Find Full Text PDF

Objective: This study aimed to determine the role of brain MRI post-processing method MAP07 (Morphometric Analysis Program) in detecting epileptogenic brain lesions in patients with pharmacoresistant epilepsy (PE). MAP07 is a sophisticated diagnostic program that offers several morphometric maps and facilitates the detection and localization of hippocampal sclerosis (HS), focal cortical dysplasias (FCD), and other types of cortical malformations, which could be undetected by conventional visual MRI analysis (CVA).

Methods: 120 patients aged > 16 years with PE have been recruited.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!